This week's topics include time to reimbursement for drugs from approval, screening after a false-positive mammogram, RSV vaccination and hospitalization, and emissions from inhalers. Elizabeth: How ...
In the TRUST-II trial, 85 percent of ROS1 TKI-naïve NSCLC patients and in 62 percent of TKI-pretreated patients responded to the next-generation ROS1 inhibitor.
Some results have been hidden because they may be inaccessible to you